Literature DB >> 21222501

Comparison of mesenchymal stromal cells from young healthy donors and patients with severe chronic coronary artery disease.

Tina Friis1, Mandana Haack-Sørensen, Susanne Kofoed Hansen, Louise Hansen, Lene Bindslev, Jens Kastrup.   

Abstract

BACKGROUND: It has been questioned whether bone marrow-derived mesenchymal stromal cells (MSCs) from patients with ischemic heart disease are suitable for use in regenerative stem cell therapy. We compared MSCs from patients with chronic coronary artery disease (CAD) and MSCs from young healthy donors with respect to phenotype, proliferation and endothelial differentiation capacity.
METHODS: MSCs from 16 young healthy donors and 15 elderly CAD patients were isolated, expanded by ex-vivo cultivation for two cell passages and characterized by flow cytometry, real time PCR and angiogenesis assay.
RESULTS: MSCs from healthy donors and CAD patients expressed the same surface markers and had similar proliferation capacity. In both groups VEGF-stimulation significantly increased the expression of the endothelial genes thrombospondin 1, Tie-2 and von Willebrand Factor and induced the capacity to form ring structures on extracellular matrix. DISCUSSION: MSCs from young healthy donors and CAD patients proliferate equally well, express the same surface markers and increase in endothelial gene expression and ring structure formation capacity in the angiogenesis assay upon VEGF-stimulation. MSCs from CAD patients do not seem to be inferior to MSCs from young healthy donors thus indicating that autologous MSCs may be suitable for cell therapy in CAD patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21222501     DOI: 10.3109/00365513.2010.550310

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  9 in total

1.  Expansion and angiogenic potential of mesenchymal stem cells from patients with critical limb ischemia.

Authors:  Luke Brewster; Scott Robinson; Ruoya Wang; Sarah Griffiths; Haiyan Li; Alexandra Peister; Ian Copland; Todd McDevitt
Journal:  J Vasc Surg       Date:  2016-02-24       Impact factor: 4.268

Review 2.  Stem cell therapy to treat heart ischaemia: implications for diabetes cardiovascular complications.

Authors:  Abbas Ali Qayyum; Anders Bruun Mathiasen; Jens Kastrup
Journal:  Curr Diab Rep       Date:  2014-12       Impact factor: 4.810

3.  Mesenchymal stromal cell phenotype is not influenced by confluence during culture expansion.

Authors:  Mandana Haack-Sørensen; Susanne Kofoed Hansen; Louise Hansen; Michael Gaster; Poul Hyttel; Annette Ekblond; Jens Kastrup
Journal:  Stem Cell Rev Rep       Date:  2013-02       Impact factor: 5.739

4.  Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls.

Authors:  Hendrik Gremmels; Martin Teraa; Paul Ha Quax; Krista den Ouden; Joost O Fledderus; Marianne C Verhaar
Journal:  Mol Ther       Date:  2014-09-01       Impact factor: 11.454

Review 5.  Surfing the clinical trials of mesenchymal stem cell therapy in ischemic cardiomyopathy.

Authors:  Iman Razeghian-Jahromi; Anthony G Matta; Ronan Canitrot; Mohammad Javad Zibaeenezhad; Mahboobeh Razmkhah; Anahid Safari; Vanessa Nader; Jerome Roncalli
Journal:  Stem Cell Res Ther       Date:  2021-06-23       Impact factor: 6.832

6.  Stem cells therapy for cardiovascular repair in ischemic heart disease: How to predict and secure optimal outcome?

Authors:  Jens Kastrup
Journal:  EPMA J       Date:  2011-02-08       Impact factor: 6.543

7.  Identical effects of VEGF and serum-deprivation on phenotype and function of adipose-derived stromal cells from healthy donors and patients with ischemic heart disease.

Authors:  Bjarke Follin; Josefine Tratwal; Mandana Haack-Sørensen; Jens Jørgen Elberg; Jens Kastrup; Annette Ekblond
Journal:  J Transl Med       Date:  2013-09-18       Impact factor: 5.531

8.  Identification of a common reference gene pair for qPCR in human mesenchymal stromal cells from different tissue sources treated with VEGF.

Authors:  Josefine Tratwal; Bjarke Follin; Annette Ekblond; Jens Kastrup; Mandana Haack-Sørensen
Journal:  BMC Mol Biol       Date:  2014-05-28       Impact factor: 2.946

Review 9.  Mesenchymal Stromal Cell Characteristics and Regenerative Potential in Cardiovascular Disease: Implications for Cellular Therapy.

Authors:  F C C van Rhijn-Brouwer; H Gremmels; J O Fledderus; M C Verhaar
Journal:  Cell Transplant       Date:  2018-06-13       Impact factor: 4.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.